Udaya Rangaswamy
Director - Translational Biology Rondo Therapeutics
Dr. Udaya Rangaswamy leads the Translational Biology team at Rondo Therapeutics, overseeing preclinical development of CD28-based bispecific T cell engagers for solid tumors. Her team bridges discovery and clinical development through in vivo efficacy studies, patient-derived analyses, and regulatory activities. Dr. Rangaswamy specializes in translating in vitro findings to animal models and managing CRO partnerships for preclinical and toxicology studies. Her work focuses on overcoming CD3-based therapy limitations by targeting co-stimulatory receptors, developing monotherapy approaches for immunologically active tumors and combination strategies for colder microenvironments.
Seminars
Thursday 29th January 2026
Analyzing RNDO-564 Efficacy with Cell Line & Syngenic Mouse Model to Deliver Robust Anti-Tumor Responses
9:00 am
- Harnessing affinity-tuned CD28 costimulation with high-affinity Nectin-4 targeting to maximize localized T-cell activation and potentiate anti-tumor cytotoxicity
- Demonstrating strong in vitro activity through enhanced cytotoxicity and cytokine release against Nectin-4–positive tumor cell lines under signal 1 conditions
- Achieving dose-dependent tumor growth inhibition in syngeneic models and favorable tolerability in primates to validate translational therapeutic potential
